Dmytrenko, I.V. et al. 2019. SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS. International Journal of Medicine and Medical Research. 5, 1 (Jul. 2019), 33–39. DOI:https://doi.org/10.11603/ijmmr.2413-6077.2019.1.10305.